Malignant pleural effusions (MPE) are a common pathology, treated by respiratory
physicians and thoracic surgeons alike. In recent years, several well-designed randomized …

Background Approximately half of all patients with metastatic cancer develop a malignant
pleural effusion which is likely to lead to a significant reduction in quality of life secondary to …

INTRODUCTION The discovery of malignant cells in pleural fluid and/or parietal pleura
signifies disseminated or advanced disease and a reduced life expectancy in patients with …

Local anaesthetic thoracoscopy: British Thoracic Society pleural disease guideline 2010 |
Thorax Skip to main content Viewing from: Google Indexer BMJ Journals Subscribe Log In More …

Study objective To demonstrate the efficacy, safety, and appropriate mode of instillation of
talc for sclerosis in treatment of malignant pleural effusions (MPEs) Design A prospective …

2 PATHOPHYSIOLOGY The pleura consists of five main anatomical compartments (fig 2):
the parietal systemic circulation (branches of the intercostal and internal mammary arteries) …

Introduction Malignant pleural effusions (MPEs) are a common cause of dyspnea in patients
with advanced cancer. Tunnelled pleural catheters (TPCs) can be used in patients with this …

Background Talc is the most effective chemical pleurodesis agent for patients with malignant
pleural effusion. However, concerns have arisen about the safety of intrapleural application …

Malignant pleural effusions (MPEs) are an important complication for patients with
intrathoracic and extrathoracic malignancies. Median survival after diagnosis of an MPE is 4 …

Background Pleurodesis is important in the management of malignant pleural effusions, but
no consensus exists on the optimal agent or methods of pleurodesis. How pleurodesis is …